← All organizations
Highest phase reached
Phase 3
Acquired by Ionis Pharmaceuticals, Inc. on Sep 15, 2020
Timeline
2010s
- Jul 1, 2014
Akcea Therapeutics— Founded
- Oct 5, 2018
inotersen— NDA Secondary Org
2020s
- Sep 15, 2020
Ionis Pharmaceuticals, Inc.— Acquired By
Drugs by trial phase (12 distinct, 21 trials)
Phase 3 (4 own, 0 via acquisition)
Phase 2 (3 own, 0 via acquisition)
Phase 1 (5 own, 0 via acquisition)
Indications
Studied for
- Amyloid Neuropathies
- Amyloidosis
- Cardiomyopathies
- Cardiovascular Abnormalities
- Cardiovascular Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Fatty Liver
- Hypercholesterolemia
- Hyperlipidemias
- Hyperlipoproteinemias
- Hyperlipoproteinemia Type I
- Hyperlipoproteinemia Type II
- Hypertriglyceridemia
- Lipodystrophy
- Lipodystrophy, Familial Partial
- Liver Diseases
- Non-alcoholic Fatty Liver Disease
- Polyneuropathies
- Renal Insufficiency
- Syndrome
Marketed drugs (1)
Recent trials (22)
- NCT03544060Study directorN/A—
- NCT03544060Lead sponsorN/A—
- NCT04568434CollaboratorPhase 3Dec 31, 2020
- NCT04136171CollaboratorPhase 3Nov 30, 2019
- NCT04136184CollaboratorPhase 3Oct 31, 2019
- NCT03514420Lead sponsorPhase 2May 30, 2018
- NCT03455777Lead sponsorPhase 2Apr 12, 2018
- NCT03506854Lead sponsorPhase 1Mar 20, 2018
- NCT03385239Lead sponsorPhase 2Jan 5, 2018
- NCT03392051Lead sponsorPhase 1Dec 28, 2017
- NCT03360747Lead sponsorPhase 2Dec 21, 2017
- NCT03371355Lead sponsorPhase 2Dec 18, 2017
- NCT03426033Lead sponsorPhase 1Dec 15, 2017
- NCT03070782CollaboratorPhase 2Mar 7, 2017
- NCT02910635CollaboratorPhase 1Sep 19, 2016
Details
- Founded
- Cambridge, MA, US Jul 1, 2014
- Last known activity
- Dec 31, 2020